Jaime Rosenberg

Articles

Multistakeholder Panel Weighs In on Which Factors to Consider for Reimbursement of Orphan Drugs

September 11, 2021

From the decision analysis came an agreement that reimbursement for an orphan drug should be based primarily on its effect on health-related quality of life, its effectiveness, and the availability of other treatment options.

Researchers Find Insight Into Risk of Developing AML

September 10, 2021

In a recent study, researchers were able to show how different evolutionary forces in aging blood stem cells impact whether or not someone develops acute myeloid leukemia (AML), offering insight into those at higher risk of the disease.

Study Examines Treatment Link to Transplant Complication in GVHD

September 06, 2021

Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.

Murine Study Suggests Novel I-O Combo May Be Effective in CRC

September 04, 2021

The murine study, which assessed the combination of foretinib and an anti–PD-1 antibody, found that the regimen enhanced antitumor activity, offering promise in a cancer that has seen less success with immunotherapies than others.

Describing Sensitivity of ddPCR in Philadelphia-Positive ALL

September 02, 2021

The study, using a BCR/ABL1 assay, found that the novel method is able to detect minimal residual disease (MRD) in a larger range of patients compared with quantitative real‐time polymerase chain reaction, the method currently used to detect MRD.

Researchers Identify Potential Approach to Overcoming CLL CAR T-Cell Resistance

September 01, 2021

The findings, if confirmed in subsequent research, could prove to have significant implications, as only a small subset of patients with chronic lymphocytic leukemia (CLL) respond to chimeric antigen receptor (CAR) T-cell therapy.